Correction {#Sec1}
==========

Upon publication of this article \[[@CR1]\], it was noticed that there were some inconsistencies in Tables [1](#Tab1){ref-type="table"}, [2](#Tab2){ref-type="table"} and [3](#Tab3){ref-type="table"}. Some of the superscript letters were incorrectly assigned. Please see below the correct tables:Table 1Comparisons of baseline and follow-up characteristics by Aβ and WMH statusAβ- WMH-Aβ- WMH+Aβ + WMH-Aβ + WMH+*n* = 140*n* = 39*n* = 63*n* = 29Baseline characteristics Age61.7 (8.3)^B,C,D^71.3 (7.7)^A,C^66.7 (7.8)^A,B,D^74.1 (5.0)^A,C^ Female, n94 (67)^C^23 (59)32 (51)^A^16 (55) Education in years10.9 (3.1)11.9 (3.3)11.1 (3.1)10.3 (2.9) Hypertension, n^\*^43 (34)9 (25)15 (25)9 (32) Obesity, n^\*^15 (14)3 (11)4 (8)4 (21) Diabetes, n^\*^16 (21)3 (15)3 (7)5 (28) APOE-ε4 carrier, n^\*^33 (51)^B^5 (24)^A,C,D^29 (62)^B^10 (56)^B^ Diagnosis MCI, n70 (50)^D^21 (54)^D^40 (64)22 (76)^A,B^  amnestic MCI (% within MCI group)40 (57)15 (71)27 (68)17 (77)  non-amnestic MCI (% within MCI group)30 (43)6 (29)13 (33)5 (23) CSF Aβ 1--42, pg/ml973.6 (312.0)^C,D^885.0 (242.0)^C,D^404.3 (102.6)^A,B^419.3 (97.2)^A,B^ White matter hyperintensities^†^0.7 (0.5)^B,D^2.3 (0.4)^A,C^0.8 (0.4)^B,D^2.4 (0.5)^A,C^Follow-up characteristics Follow-up time2.1 (1.5)2.2 (1.3)2.1 (1.2)2.4 (1.2) Time to progression to dementia1.3 (0.5)^B^2.0 (0.7)^A^1.7 (0.7)2.1 (1.2) Progression to dementia, n8 (6)^B,C,D^9 (23)^A^18 (29)^A^11 (38)^A^- AD-type dementia, n2 (1)^B,C,D^7 (18)^A^18 (29)^A^10 (35)^A^- Vascular dementia, n0 (0)2 (5)0 (0)1 (3)- Frontotemporal dementia, n4 (3)0 (0)0 (0)0 (0)- Lewy Body dementia, n1 (1)0 (0)0 (0)0 (0)- Dementia with unknown etiology, n1 (1)0 (0)0 (0)0 (0)Results are mean (SD) for continuous variables or frequency (%). Hypertension, obesity, diabetes and APOE ε4 genotype were only available in a subgroup of the sampleAbbreviations: *Aβ* amyloid-beta, *AD* Alzheimer's disease, *APOE* Apolipoprotein E, *MCI* mild cognitive impairment^†^WMH measured by the Fazekas scale, range 0--3^A^*p* \< 0.05 compared to Aβ- WMH-^B^*p* \< 0.05 compared to Aβ- WMH+^C^*p* \< 0.05 compared to Aβ + WMH-^D^*p* \< 0.05 compared to Aβ + WMH+Table 2Values of neurodegenerative markers by Aβ/WMH groupsAβ- WMH-Aβ- WMH+Aβ + WMH-Aβ + WMH+Neurodegeneration markersn = 140n = 39n = 63n = 29MTA score1.2 (1.2)^B,C,D^2.6 (1.6)^A,D^2.1 (1.6)^A,D^3.4 (1.8)^A,B,C^ MTA abnormal, n62 (45)^B,C,D^32 (82)^A^41 (67)^A,D^26 (93)^A,C^P-tau, pg/ml54.5 (27.7)^C^63.2 (29.3)77.0 (56.3)^A^65.2 (38.2) P-tau abnormal, n53 (38)^C^22 (58)45 (71)^A^15 (52)T-tau, pg/ml314.7 (202.0)^B,C,D^438.4 (248.0)^A^499.3 (413.8)^A^426.2 (275.2)^A^ T-tau abnormal, n36 (26)^B,C,D^20 (53)^A^36 (57)^A^14 (48)^A^Results are mean (SD) and number (%). All analyses were adjusted for study, baseline diagnosis and demographics*Abbreviations*: *Aβ* amyloid-beta, *MTA* medial temporal lobe atrophy, *P-tau* phosphorylated tau, *T-tau* Total tau, *WMH* white matter hyperintensities^A^*p* \< 0.05 compared to Aβ- WMH-^B^*p* \< 0.05 compared to Aβ- WMH+.^C^p \< 0.05 compared to Aβ + WMH-.^D^p \< 0.05 compared to Aβ + WMH+.Table 3Cognitive performance and decline by Aβ/WMH groupsAβ- WMH-Aβ- WMH+Aβ + WMH-Aβ + WMH+MMSE^\*^n140396227Baseline27.79 (27.39, 28.19)27.52 (26.83, 28.21)27.20 (26.62, 27.78)27.40 (26.54, 28.25)Slope−0.01 (− 0.15, 0.12)− 0.29 (− 0.55, − 0.02)−0.22 (− 0.44, − 0.01)− 0.31 (− 0.62, 0.00)Memory delayed recall z-scoren133375827Baseline−0.48 (− 0.72, − 0.24)^B,C,D^−1.04 (− 1.48, − 0.61)^A^−1.04 (− 1.41, − 0.68)^A^−1.33 (− 1.86, − 0.80)^A^Slope0.05 (− 0.03, 0.13)0.02 (− 0.12, 0.17)0.02 (− 0.11, 0.14)−0.07 (− 0.24, 0.09)Executive functioning z-scoren130376024Baseline−0.48 (− 0.76, − 0.21)−0.41 (− 0.92, 0.09)−0.78 (− 1.18, − 0.37)−1.12 (− 1.73, − 0.50)Slope0.06 (− 0.02, 0.13)−0.00 (− 0.15, 0.15)−0.03 (− 0.16, 0.10)−0.04 (− 0.23, 0.15)Results are mean (95% confidence interval). Bold slope estimates = *p* \< 0.05. All analyses were adjusted for study. The analyses on MMSE scores were also corrected for demographics and baseline diagnosis*Abbreviations*: *Aβ* amyloid-beta, *MMSE* mini mental state examination, *WMH* white matter Hyperintensities^A^p \< 0.05 compared to Aβ- WMH-^B^p \< 0.05 compared to Aβ- WMH+.^C^p \< 0.05 compared to Aβ + WMH-.^D^p \< 0.05 compared to Aβ + WMH+.
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